T-AIII has been reported to induce multidrug resistance reversal by inhibiting the expression of MDR1 and MRP1 in human chronic myelogenous leukemia K562/ADM cells[30]. Here, ABCB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.